|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis.
|
21930937 |
2011 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells.
|
21456062 |
2011 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
|
20729295 |
2010 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Retroviral expression of constitutively active Notch-1 in human prostate tumor cell lines resulted in increased PTEN gene expression.
|
19479935 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
|
19396168 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
|
19116269 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Alterations in the PIK3CA and PTEN genes were assessed in 40 prostate tumors (radical prostatectomy samples).
|
19443396 |
2009 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
[Role of PTEN protein in multidrug resistance of prostate cancer cells].
|
18702307 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
|
19081794 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Is PTEN loss associated with clinical outcome measures in human prostate cancer?
|
18854827 |
2008 |
|
Prostatic Neoplasms
|
0.600 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
The role of PTEN in prostate cancer cell tropism to the bone micro-environment.
|
17347137 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Integrative molecular concept modeling of prostate cancer progression.
|
17173048 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.
|
17372210 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Pten inactivation and the emergence of androgen-independent prostate cancer.
|
17638861 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
|
17826033 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.
|
17616684 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
|
16697957 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.
|
16432235 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
|
16421604 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is lost as a function of prostate tumor androgen dependence.
|
16637073 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Expression of mTOR signaling pathway markers in prostate cancer progression.
|
16652388 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors.
|
16496415 |
2006 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Significantly reduced PTEN expression was observed in AI versus benign and hormone naïve prostate tumors.
|
16496415 |
2006 |